Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07157787 · ClinicalTrials.gov registry record · Phase 2
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
A Phase 2 study of Primary Membranous Nephropathy, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT07157787: Recruiting Phase 2 study of Primary Membranous Nephropathy, sponsored by Alexion Pharmaceuticals.
NCT07157787 is a Phase 2 study of Primary Membranous Nephropathy that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 30 participants, below the 133-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07157787, a Phase 2 study of Primary Membranous Nephropathy, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALXN1920
Study Locations (20)
Other
- Research Site - Buenos Aires
- Research Site - CABA
- Research Site - Ciudad de Buenos Aires
- Research Site - Rosario
- Research Site - Santa Fe
- Research Site - Santa Fe
- Research Site - Gosford
- Research Site - Parkville
- Research Site - Southport
- Research Site - Recife
- Research Site - Salvador
- Research Site - São Paulo
- Research Site - São Paulo
- Research Site - Baotou
- Research Site - Beijing
California
- Research Site - Loma Linda
- Research Site - San Diego
Minnesota
- Research Site - Minneapolis
- Research Site - Rochester
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2027-02-12 |
| Phase | Phase 2 |
What NCT07157787 shows while recruiting
NCT07157787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07157787 names 20 study sites across 4 states, led by Other, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT07157787 about?
NCT07157787 is a clinical study titled "Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)". The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).
What is the current status of trial NCT07157787?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-09-19. Estimated completion is 2027-02-12.
What conditions does trial NCT07157787 study?
This clinical trial studies the following conditions: Primary Membranous Nephropathy.
What interventions are being tested in trial NCT07157787?
The interventions under investigation include: Placebo (DRUG), ALXN1920 (DRUG).
Who is sponsoring clinical trial NCT07157787?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07157787 being conducted?
This trial has 20 study locations across California, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Membranous Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07157787's enrollment target sits among peer trials
30 9th of 8 the lowest of 8 other Primary Membranous Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Membranous Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of WAL0921 in Patients With Glomerular Kidney Diseases
RECRUITING · Phase 2
-
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
RECRUITING · Phase 2
-
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 3
-
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI